Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1983;16(Suppl 2):299S–307S. doi: 10.1111/j.1365-2125.1983.tb02304.x

Pharmacokinetics of brotizolam in the elderly

Roeline Jochemsen, K L Nandi, D Corless, J G J Wesselman, D D Breimer
PMCID: PMC1428236  PMID: 6661375

Abstract

1 Disposition of brotizolam in patients aged 71-93 years was compared with that of healthy young subjects aged 21-26 years.

2 The mean elimination half-life of brotizolam was about twice as long in the elderly as in the young subjects: 9.3 (4.0-19.5) h and 4.8 (3.1-6.3) h respectively. Increase in elimination half-life was attributable to a decrease in hepatic clearance, i.e. 40 (20-58) ml/min in the elderly and 109 (77-156) ml/min in the young. Volume of distribution and protein binding were the same with mean values of 0.56 (0.45-0.72) l/kg and 9.0 (6.8-11.9)% in the elderly and 0.63 (0.40-0.77) l/kg and 8.4 (7.5-9.4)% in the young.

3 Absorption rate of brotizolam was relatively slow in the elderly with a mean peak time of 1.7 h compared with 1.1 h in the young. Mean bioavailability was almost 70% for both groups. Normalized for body weight and dose (0.25 mg) mean peak concentrations were 247 (137-395) ng ml-1 kg in the young and 343 (251-446) ng ml-1 kg in the elderly.

4 It is unlikely that substantial drug accumulation will occur if elderly patients ingest 0.25 mg brotizolam nightly.

Keywords: brotizolam, pharmacokinetics, young subjects, elderly patients

Full text

PDF
299S

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abernethy D. R., Greenblatt D. J. Impairment of antipyrine metabolism by low-dose oral contraceptive steroids. Clin Pharmacol Ther. 1981 Jan;29(1):106–110. doi: 10.1038/clpt.1981.17. [DOI] [PubMed] [Google Scholar]
  2. Allen M. D., Greenblatt D. J., Harmatz J. S., Shader R. I. Desmethyldiazepam kinetics in the elderly after oral prazepam. Clin Pharmacol Ther. 1980 Aug;28(2):196–202. doi: 10.1038/clpt.1980.150. [DOI] [PubMed] [Google Scholar]
  3. Divoll M., Greenblatt D. J., Harmatz J. S., Shader R. I. Effect of age and gender on disposition of temazepam. J Pharm Sci. 1981 Oct;70(10):1104–1107. doi: 10.1002/jps.2600701004. [DOI] [PubMed] [Google Scholar]
  4. Eichelbaum M. Drug metabolism in thyroid disease. Clin Pharmacokinet. 1976;1(5):339–350. doi: 10.2165/00003088-197601050-00002. [DOI] [PubMed] [Google Scholar]
  5. Greenblatt D. J., Allen M. D., Harmatz J. S., Shader R. I. Diazepam disposition determinants. Clin Pharmacol Ther. 1980 Mar;27(3):301–312. doi: 10.1038/clpt.1980.40. [DOI] [PubMed] [Google Scholar]
  6. Greenblatt D. J., Allen M. D., Locniskar A., Harmatz J. S., Shader R. I. Lorazepam kinetics in the elderly. Clin Pharmacol Ther. 1979 Jul;26(1):103–113. doi: 10.1002/cpt1979261103. [DOI] [PubMed] [Google Scholar]
  7. Greenblatt D. J., Divoll M., Abernethy D. R., Harmatz J. S., Shader R. I. Antipyrine kinetics in the elderly: prediction of age-related changes in benzodiazepine oxidizing capacity. J Pharmacol Exp Ther. 1982 Jan;220(1):120–126. [PubMed] [Google Scholar]
  8. Greenblatt D. J., Divoll M., Harmatz J. S., MacLaughlin D. S., Shader R. I. Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs. Clin Pharmacol Ther. 1981 Oct;30(4):475–486. doi: 10.1038/clpt.1981.191. [DOI] [PubMed] [Google Scholar]
  9. Greenblatt D. J., Divoll M., Harmatz J. S., Shader R. I. Oxazepam kinetics: effects of age and sex. J Pharmacol Exp Ther. 1980 Oct;215(1):86–91. [PubMed] [Google Scholar]
  10. Jochemsen R., Van Beusekom B. R., Spoelstra P., Janssens A. R., Breimer D. D. Effect of age and liver cirrhosis on the pharmacokinetics of nitrazepam. Br J Clin Pharmacol. 1983 Mar;15(3):295–302. doi: 10.1111/j.1365-2125.1983.tb01502.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Jochemsen R., Wesselman J. G., Hermans J., van Boxtel C. J., Breimer D. D. Pharmacokinetics of brotizolam in healthy subjects following intravenous and oral administration. Br J Clin Pharmacol. 1983;16 (Suppl 2):285S–290S. doi: 10.1111/j.1365-2125.1983.tb02302.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Jochemsen R., Wesselman J. G., van Boxtel C. J., Hermans J., Breimer D. D. Comparative pharmacokinetics of brotizolam and triazolam in healthy subjects. Br J Clin Pharmacol. 1983;16 (Suppl 2):291S–297S. doi: 10.1111/j.1365-2125.1983.tb02303.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kangas L., Iisalo E., Kanto J., Lehtinen V., Pynnönen S., Ruikka I., Salminen J., Sillanpä M., Syvälahti E. Human pharmacokinetics of nitrazepam: effect of age and diseases. Eur J Clin Pharmacol. 1979 Apr 17;15(3):163–170. doi: 10.1007/BF00563100. [DOI] [PubMed] [Google Scholar]
  14. Klotz U., Avant G. R., Hoyumpa A., Schenker S., Wilkinson G. R. The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest. 1975 Feb;55(2):347–359. doi: 10.1172/JCI107938. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Klotz U., Müller-Seydlitz P. Altered elimination of desmethyldiazepam in the elderly. Br J Clin Pharmacol. 1979 Jan;7(1):119–120. doi: 10.1111/j.1365-2125.1979.tb00908.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kraus J. W., Desmond P. V., Marshall J. P., Johnson R. F., Schenker S., Wilkinson G. R. Effects of aging and liver disease on disposition of lorazepam. Clin Pharmacol Ther. 1978 Oct;24(4):411–419. doi: 10.1002/cpt1978244411. [DOI] [PubMed] [Google Scholar]
  17. Nicholson A. N., Stone B. M., Pascoe P. A. Studies on sleep and performance with a triazolo-1, 4-thienodiazepine (brotizolam). Br J Clin Pharmacol. 1980 Jul;10(1):75–81. doi: 10.1111/j.1365-2125.1980.tb00504.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Roberts R. K., Wilkinson G. R., Branch R. A., Schenker S. Effect of age and parenchymal liver disease on the disposition and elimination of chlordiazepoxide (librium). Gastroenterology. 1978 Sep;75(3):479–485. [PubMed] [Google Scholar]
  19. Saletu B., Grünberger J., Volavka J., Berner P. Classification and bioavailability studies with WE 941 by quantitative pharmaco-EEG and clinical analyses. Arzneimittelforschung. 1979;29(4):700–704. [PubMed] [Google Scholar]
  20. Sanchez-Martinez J., Landa-Palos D. M. A new thienodiazepine, brotizolam, for the treatment of insomnia. J Int Med Res. 1982;10(2):118–121. doi: 10.1177/030006058201000209. [DOI] [PubMed] [Google Scholar]
  21. Shull H. J., Wilkinson G. R., Johnson R., Schenker S. Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Ann Intern Med. 1976 Apr;84(4):420–425. doi: 10.7326/0003-4819-84-4-420. [DOI] [PubMed] [Google Scholar]
  22. Velasco M., Velasco F., Cepeda C., Romo R., Pérez-Toledo M. A. Effect of a new thienodiazepine (We-941) on sleep patterns of normal and insomniac subjects. Neuropharmacology. 1981 May;20(5):461–468. doi: 10.1016/0028-3908(81)90178-7. [DOI] [PubMed] [Google Scholar]
  23. Vestal R. E. Drug use in the elderly: a review of problems and special considerations. Drugs. 1978 Oct;16(4):358–382. doi: 10.2165/00003495-197816040-00004. [DOI] [PubMed] [Google Scholar]
  24. Vestal R. E., Wood A. J. Influence of age and smoking on drug kinetics in man: studies using model compounds. Clin Pharmacokinet. 1980 Jul-Aug;5(4):309–319. doi: 10.2165/00003088-198005040-00001. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES